Detailed mechanism of action, phase 2/3 clinical trial findings, hepatic fat reduction endpoints, and receptor comparison.
Retatrutide is an investigational triple-hormone receptor agonist ("triple G") developed by Eli Lilly. It targets three distinct metabolic pathways simultaneously: GLP-1, GIP, and glucagon.
Weight Loss: In Phase 2 clinical trials published in the New England Journal of Medicine, participants taking the highest dose (12 mg weekly) achieved an average weight reduction of approximately 24.2% over 48 weeks.
TRIUMPH Phase 3 Trials: Ongoing late-stage clinical programs are evaluating its safety and efficacy for chronic weight management, type 2 diabetes, obstructive sleep apnea, and osteoarthritis.
FDA Status: Retatrutide is not FDA-approved. It cannot be legally prescribed by healthcare providers or dispensed by commercial/compounding pharmacies outside authorized clinical trials.
Timeline: Eli Lilly expects to complete Phase 3 studies and submit regulatory filings around 2027.
Safety & "Research" Peptides: Unregulated online sellers advertising retatrutide as "research peptides" or custom compounds carry significant health risks, including unverified purity, contamination, and dosing errors.
For current medically supervised options, approved alternatives like tirzepatide (dual GLP-1/GIP) or semaglutide (GLP-1) are available through healthcare providers. You can also explore active, authorized studies directly through the U.S. National Library of Medicine Clinical Trials Registry.
Head-to-head mechanistic targets, trial weight loss metrics, and approval status.
| Feature | Semaglutide (Ozempic / Wegovy) | Tirzepatide (Mounjaro / Zepbound) | Retatrutide (Investigational) |
|---|---|---|---|
| Mechanism / Receptor Targets | Single Agonist: • GLP-1 |
Dual Agonist: • GLP-1 • GIP |
Triple Agonist ("Triple G"): • GLP-1 • GIP • Glucagon |
| Primary Metabolic Actions | Slows gastric emptying, suppresses appetite, improves glucose-dependent insulin secretion. | Combines appetite suppression with enhanced fat metabolism and insulin sensitivity. | Suppresses appetite while actively increasing energy expenditure (calorie burning) and liver fat clearance. |
| Clinical Weight Loss Data (Top Dose) | ~15% average body weight loss at 68 weeks (STEP 1 trial). | ~20.9% – 22.5% average body weight loss at 72 weeks (SURMOUNT-1 trial). | ~24.2% – 28.7% average body weight loss at 48–68 weeks (Phase 2 / TRIUMPH Phase 3 trials). |
| FDA Approval Status | Approved: • Type 2 diabetes (Ozempic) • Chronic weight management & CV risk reduction (Wegovy) |
Approved: • Type 2 diabetes (Mounjaro) • Chronic weight management & OSA (Zepbound) |
Not Approved: • Currently in late-stage Phase 3 clinical trials (filings expected ~2027). |
| Dosing Route & Frequency | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection (in clinical trials) |
| Common Side Effect Profile | Predominantly gastrointestinal (nausea, diarrhea, constipation, vomiting). | Predominantly gastrointestinal; similar tolerability to GLP-1 mono-agonists. | Gastrointestinal effects; mild, transient increases in heart rate during dose escalation. |
While GLP-1 and GIP drive weight loss almost entirely by curbing appetite and regulating insulin, glucagon receptor (GCGR) activation adds a distinct metabolic engine: it actively forces the body to burn more calories at rest.
Glucagon binds directly to GCGR receptors in hepatocytes (liver cells), stimulating mitochondrial β-oxidation (the breakdown of fatty acids into energy). It upregulates hepatic energy-consuming pathways (such as gluconeogenesis and ureagenesis), converting stored hepatic triglycerides into heat and usable cellular energy. This is also why retatrutide shows dramatic reductions in non-alcoholic fatty liver disease (MASH/MASLD).
Central and peripheral glucagon signaling stimulates the sympathetic nervous system. This triggers thermogenesis in brown adipose tissue (BAT) and promotes the "browning" of white adipose tissue (WAT) via uncoupling protein 1 (UCP1), causing cells to dissipate energy as heat rather than storing it as fat.
| Hormone Pathway | Primary Site of Action | Core Effect on Energy Balance | Primary Metabolic Function |
|---|---|---|---|
| GLP-1 | Hypothalamus, Vagus nerve, Stomach | Decreases Energy In | Slows gastric emptying, induces early satiety, reduces meal size. |
| GIP | Hypothalamus, Subcutaneous fat, Pancreas | Decreases Energy In & Buffers Lipid Storage | Synergizes with GLP-1 to suppress nausea and appetite; enhances lipid buffering in fat tissue. |
| Glucagon | Liver, Brown/Beige fat, Central nervous system | Increases Energy Out | Directly elevates resting metabolic rate (RMR) and lipid oxidation. |
In basic physiology, glucagon raises blood sugar by releasing glucose from the liver. Retatrutide resolves this through balanced synergy:
In Phase 2 sub-study data (published in Nature Medicine by Sanyal et al. and presented at the American Association for the Study of Liver Diseases), retatrutide demonstrated unprecedented reductions in hepatic steatosis (liver fat). The trial evaluated participants with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD/NASH) who had ≥10% baseline liver fat measured via MRI proton density fat fraction (MRI-PDFF).
| Metric / Endpoint | Placebo | 1 mg | 4 mg | 8 mg | 12 mg |
|---|---|---|---|---|---|
| Relative Liver Fat Reduction (Week 24) | +0.3% | -42.9% | -57.0% | -81.4% | -82.4% |
| Relative Liver Fat Reduction (Week 48) | -4.6% | -51.3% | -59.0% | -81.7% | -86.0% |
| Normalization Rate (<5% Liver Fat at 24 Wks) | 0% | 27% | 52% | 79% | 86% |
| Normalization Rate (<5% Liver Fat at 48 Wks) | 0% | 57% | 29% | 89% | 93% |
*(All active doses achieved P < 0.001 versus placebo).*
| Feature / Clinical Endpoint | Tirzepatide (SYNERGY-NASH Phase 2) | Retatrutide (MASLD Phase 2a Sub-study) |
|---|---|---|
| Primary Mechanism | Dual agonist: GLP-1 + GIP | Triple agonist: GLP-1 + GIP + Glucagon |
| Study Population | 190 adults with biopsy-confirmed MASH and moderate-to-severe fibrosis (F2–F3). | 98 adults with obesity and MASLD with ≥10% baseline liver fat (imaging-focused). |
| Study Duration & Delivery | 52 weeks; once-weekly injection (5, 10, 15 mg) | 48 weeks; once-weekly injection (1, 4, 8, 12 mg) |
| Liver Fat Reduction (MRI-PDFF) | ~50% to 65% relative reduction in liver fat at top doses. | -86.0% relative reduction at 12 mg (-81.7% at 8 mg). |
| Steatosis Normalization Rate (Liver fat <5%) | ~50% – 60% of participants achieved normal liver fat levels. | 93% of participants achieved normal liver fat at 12 mg (89% at 8 mg). |
| Histological MASH Resolution (Without worsening fibrosis) | Primary Endpoint: • 15 mg: 73.3% (62% per-protocol) • 10 mg: 62.8% (56% per-protocol) • 5 mg: 51.8% (44% per-protocol) • Placebo: 13.2% (10% per-protocol) |
Not formally biopsied in Phase 2 (measured via MRI-PDFF and non-invasive biomarkers). Full histology evaluated in Phase 3. |
| Fibrosis Improvement (≥1 stage without MASH worsening) | Key Secondary Endpoint: • 5 mg: 59.1% • 10 mg: 53.3% • 15 mg: 54.2% • Placebo: 32.8% |
Indirectly measured via biomarker drops (FIB-4, K-18, ALT/AST). Histology endpoints evaluated in Phase 3. |
| Primary Driver of Hepatic Effect | Weight loss, reduced lipotoxicity, systemic insulin sensitization, and adipose tissue lipid buffering. | Systemic caloric restriction plus direct hepatic β-oxidation (mitochondrial fat burning driven by glucagon). |
1. Study Design & Diagnostic Endpoints: Tirzepatide (SYNERGY-NASH) enrolled patients with advanced, biopsy-proven liver disease (stages F2 and F3 fibrosis) to prove histological resolution. Retatrutide (Nature Medicine Sub-study) evaluated patients using non-invasive MRI-PDFF imaging to measure the speed and magnitude of liver fat clearance.
2. The Glucagon Advantage on Steatosis: Tirzepatide delivers exceptional biopsy-proven resolution rates, but retatrutide's 86% average liver fat reduction and 93% complete normalization rate represent the highest degree of liver "defatting" recorded for any metabolic compound in clinical development. The glucagon receptor acts directly on hepatocytes to metabolize stored triglycerides into energy.
For complete official pharmaceutical trial updates and Eli Lilly research publications, you can research directly through Eli Lilly's news room. You are responsible for conducting your own independent literature research.
This phrase is a quality-assurance claim stating that every manufactured batch of the peptide has been lab-tested and verified to contain at least 99% of the intended molecule, using industry gold-standard testing methods.
A "lot" (or batch) is a specific production run. "All lots" means every single batch manufactured undergoes testing, not just an occasional sample.
At least 99% of the peptide material present is the exact, full-length target peptide. The remaining <1% consists of minor synthesis byproducts (like truncated peptide chains or deletion sequences).
A separation technique that pumps the liquid sample through a column under high pressure. It physically separates the target peptide from impurities and measures purity percentage based on UV absorption peaks.
A detection method paired with HPLC that measures the exact mass-to-charge ratio (m/z) of the molecules. It confirms the chemical identity and exact molecular weight to ensure the peptide synthesized is actually the intended compound, not a lookalike.
Peptide synthesis is built step-by-step, amino acid by amino acid. Errors during synthesis can create incomplete chains or modified sequences. Pairing HPLC with Mass Spectrometry ensures two critical things: HPLC confirms how pure it is, and MS confirms what it is.